Physician profile
Jerry Ellen Schonfeld
NPI 1730365701
$6,364.58
in general payments reported to CMS, 2019-2025
13 companies · $4,425 in 2025
The $4,425 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $156 · 2022: $148 · 2023: $1,164 · 2024: $472 · 2025: $4,425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,256 · Food and Beverage: $1,106 · Consulting Fee: $699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,256.00 |
| Food and Beverage | $1,105.65 |
| Consulting Fee | $699.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $5,528.44 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $224.17 | 2022-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $203.84 | 2021-2024 | Eohilia, Gattex |
| Regeneron Pharmaceuticals, INC. | $107.03 | 2025 | Dupixent |
| Madrigal Pharmaceuticals | $78.98 | 2024 | Resmetirom |
| Albireo Pharma, INC. | $49.63 | 2024 | Bylvay |
| Mirum Pharmaceuticals, INC. | $44.04 | 2023-2024 | Livmarli |
| Kyowa Kirin, INC. | $23.25 | 2023 | |
| Celltrion USA INC. | $22.74 | 2024 | Zymfentra |
| Ironwood Pharmaceuticals, INC | $21.94 | 2023 | Linzess |
| Nestle Healthcare Nutrition INC. | $21.77 | 2023 | |
| Qol Medical, LLC | $21.51 | 2024 | Sucraid |
| Abbvie INC. | $17.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Schonfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.